Updated PI-QUAL v2: Enhanced Standardized Scoring for Prostate MRI Quality
Overview
The updated PI-QUAL v2 scoring system provides a simplified, reproducible method to assess prostate MRI image quality, accommodating both multiparametric MRI with and without contrast. This revision addresses limitations of the original PI-QUAL, aiming to standardize quality assessment across diverse clinical scenarios and improve diagnostic accuracy.
Background
Multiparametric MRI (mpMRI) has revolutionized prostate cancer diagnosis by reducing unnecessary biopsies and improving detection of clinically significant cancers. High-quality MRI images are essential for accurate lesion detection, staging, and management decisions. Despite PI-RADS technical standards, image quality varies widely due to factors like patient motion, hardware differences, and artefacts. The original PI-QUAL scoring system was developed to standardize image quality assessment but was limited to mpMRI with contrast and lacked applicability in broader clinical contexts. PI-QUAL v2 was developed by the ESUR prostate cancer working group to overcome these limitations and enhance routine clinical use.
Data Highlights
Aspect
Details
PI-QUAL v1
5-point scale; mpMRI only; includes T2-WI, DWI, DCE sequences
Limitations of PI-QUAL v1
Not suitable for MRI without contrast; limited objective evaluation; restricted clinical applicability
PI-QUAL v2 Improvements
Accommodates MRI without contrast; simplified scoring; reproducible and applicable across clinical scenarios
Common Artefacts Affecting Quality
Motion artefacts, susceptibility artefacts (rectal gas, metal), chemical shift artefacts
PI-RADS v2.1 Technical Recommendations
Field strength, b values for DWI, temporal resolution for DCE, phased-array coils preferred
Key Findings
PI-QUAL v2 expands applicability to prostate MRI exams without intravenous contrast, increasing clinical utility.
The scoring system simplifies image quality assessment while maintaining reproducibility across different clinical settings.
High image quality is critical to reduce indeterminate findings and improve cancer detection and biopsy planning.
Prostate MRI quality is influenced by technical adherence to PI-RADS standards and patient-related factors such as motion and presence of metal implants.
Common artefacts include motion artefacts, susceptibility artefacts from rectal gas or metal, and chemical shift artefacts, all impacting image clarity.
PI-QUAL v2 aims to standardize quality assessment to optimize diagnostic accuracy and patient management in prostate cancer care.
Clinical Implications
Clinicians should adopt PI-QUAL v2 to objectively evaluate prostate MRI image quality, ensuring scans meet standardized criteria before interpretation. Recognizing and mitigating artefacts and adhering to PI-RADS technical recommendations can improve image quality, thereby enhancing diagnostic confidence and guiding appropriate biopsy and treatment decisions. The expanded applicability of PI-QUAL v2 supports its use in diverse clinical scenarios beyond biopsy planning.
Conclusion
PI-QUAL v2 represents a significant advancement in standardizing prostate MRI quality assessment, addressing prior limitations and facilitating broader clinical application. Its implementation is expected to improve diagnostic accuracy and patient outcomes in prostate cancer management.
References
PRECISION Trial Researchers 2018 -- Development of PI-QUAL v1
ESUR Prostate Cancer Working Group 2024 -- Updated PI-QUAL v2 Scoring System
by Maarten de Rooij, Clare Allen, Jasper J. Twilt, Linda C. P. Thijssen, Patrick Asbach, Tristan Barrett, Giorgio Brembilla, Mark Emberton, Rajan T. Gupta, Masoom A. Haider, Veeru Kasivisvanathan, Vibeke Løgager, Caroline M. Moore, Anwar R. Padhani, Valeria Panebianco, Philippe Puech, Andrei S. Purysko, Raphaële Renard-Penna, Jonathan Richenberg, Georg Salomon, Francesco Sanguedolce, Ivo G. Schoots, Harriet C. Thöny, Baris Turkbey, Geert Villeirs, Jochen Walz, Jelle Barentsz, Francesco Giganti
